These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29882452)

  • 1. Cost-effectiveness modeling for neuropathic pain treatments: investigating the relative importance of parameters using an open-source model.
    Hirst M; Bending MW; Baio G; Yesufu-Udechuku A; Dunlop WCN
    J Med Econ; 2018 Sep; 21(9):930-935. PubMed ID: 29882452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregabalin for neuropathic pain in primary care settings: recommendations for dosing and titration.
    Freynhagen R; Baron R; Kawaguchi Y; Malik RA; Martire DL; Parsons B; Rey RD; Schug SA; Jensen TS; Tölle TR; Ushida T; Whalen E
    Postgrad Med; 2021 Jan; 133(1):1-9. PubMed ID: 33423590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
    Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
    Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan.
    Akazawa M; Igarashi A; Ebata N; Murata T; Zeniya S; Haga Y; Nozawa K; Fujii K; Taguchi T
    J Pain Res; 2019; 12():2785-2797. PubMed ID: 31576163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine and pregabalin in neuropathic pain of lung cancer patients.
    Gül ŞK; Tepetam H; Gül HL
    Brain Behav; 2020 Mar; 10(3):e01527. PubMed ID: 31967742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of mirogabalin for the treatment of post-herpetic neuralgia in Taiwan.
    Ye X; Gray E; Wang YF; Wang SJ
    J Med Econ; 2020 May; 23(5):529-536. PubMed ID: 31971469
    [No Abstract]   [Full Text] [Related]  

  • 7. Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
    Barohn RJ; Gajewski B; Pasnoor M; Brown A; Herbelin LL; Kimminau KS; Mudaranthakam DP; Jawdat O; Dimachkie MM; ; Iyadurai S; Stino A; Kissel J; Pascuzzi R; Brannagan T; Wicklund M; Ahmed A; Walk D; Smith G; Quan D; Heitzman D; Tobon A; Ladha S; Wolfe G; Pulley M; Hayat G; Li Y; Thaisetthawatkul P; Lewis R; Biliciler S; Sharma K; Salajegheh K; Trivedi J; Mallonee W; Burns T; Jacoby M; Bril V; Vu T; Ramchandren S; Bazant M; Austin S; Karam C; Hussain Y; Kutz C; Twydell P; Scelsa S; Kushlaf H; Wymer J; Hehir M; Kolb N; Ralph J; Barboi A; Verma N; Ahmed M; Memon A; Saperstein D; Lou JS; Swenson A; Cash T
    JAMA Neurol; 2021 Jan; 78(1):68-76. PubMed ID: 32809014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Mirogabalin for the Treatment of Diabetic Peripheral Neuropathic Pain in Taiwan.
    Gray E; Ye X; Wang YF; Wang SJ
    Value Health Reg Issues; 2021 May; 24():148-156. PubMed ID: 33582418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain.
    Freynhagen R; Serpell M; Emir B; Whalen E; Parsons B; Clair A; Latymer M
    Pain Pract; 2015 Jan; 15(1):47-57. PubMed ID: 24279736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capsaicin 8% dermal patch in clinical practice: an expert opinion.
    Bonezzi C; Costantini A; Cruccu G; Fornasari DMM; Guardamagna V; Palmieri V; Polati E; Zini P; Dickenson AH
    Expert Opin Pharmacother; 2020 Aug; 21(11):1377-1387. PubMed ID: 32511032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Treatment Patterns and Direct Costs Associated with the Management of Neuropathic Pain.
    Machado-Duque ME; Gaviria-Mendoza A; Machado-Alba JE; Castaño N
    Pain Res Manag; 2020; 2020():9353940. PubMed ID: 32318131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the effectiveness of antidepressant therapy adjuvant to gabapentin and pregabalin for treatment of SCI-related neuropathic pain.
    McKinley EC; Richardson EJ; McGwin G; Zhang J
    J Spinal Cord Med; 2018 Nov; 41(6):637-644. PubMed ID: 29319453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Pregabalin in Neuropathic Pain after Spinal Cord Injury.
    Yang X; Zhang Y; Yu H; Sun J; He Y
    J Coll Physicians Surg Pak; 2020 Jan; 30(1):106-107. PubMed ID: 31931947
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of mirogabalin and pregabalin in Japanese patients with neuropathic pain: a retrospective cohort study.
    Nakajima R; Ooba N; Kamei M; Hashiba H; Miyazaki C
    Expert Opin Drug Saf; 2023; 22(9):841-848. PubMed ID: 36945742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful use of pregabalin by the rectal route to treat chronic neuropathic pain in a patient with complete intestinal failure.
    Doddrell C; Tripathi SS
    BMJ Case Rep; 2015 Oct; 2015():. PubMed ID: 26516246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregabalin in the treatment of postmastectomy chronic pain: Results of an open label, single-arm clinical study.
    Kaur N; Kumar A; Saxena AK; Grover RK
    Breast J; 2019 May; 25(3):465-468. PubMed ID: 30916427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of pregabalin initiation and discontinuation after its subsidy in Australia.
    Chiu T; Brett J; Pearson SA; Schaffer AL
    Br J Clin Pharmacol; 2020 Sep; 86(9):1882-1887. PubMed ID: 32153053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A probable case of pregabalin - related reversible hearing loss.
    Yılmaz R; Türk Ş; Reisli R; Tuncer Uzun S
    Agri; 2020 Apr; 32(2):103-105. PubMed ID: 32297964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert Opinion: Exploring the Effectiveness and Tolerability of Capsaicin 179 mg Cutaneous Patch and Pregabalin in the Treatment of Peripheral Neuropathic Pain.
    Huygen F; Kern KU; Pérez C
    J Pain Res; 2020; 13():2585-2597. PubMed ID: 33116801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modifying NICE's Approach to Equity Weighting.
    Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.